# Acute Heart Failure Patients With High Copeptin Treated With Tolvaptan Targets Increased AVP Activation for Treatment (ACTIVATE)

> **NCT01733134** · PHASE3 · WITHDRAWN · sponsor: **Maisel, Alan, M.D.**

## Conditions studied

- Acute Heart Failure

## Interventions

- **DRUG:** Tolvaptan
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01733134
- **Lead sponsor:** Maisel, Alan, M.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor decided to quit funding before any enrollments
- **Last updated:** 2024-11-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01733134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01733134, "Acute Heart Failure Patients With High Copeptin Treated With Tolvaptan Targets Increased AVP Activation for Treatment (ACTIVATE)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01733134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*